TANGO - Targeted Augmentation of Nuclear Gene Output - Antisense Therapy
PRECLINICAL
PHASE 1
PHASE 2
PHASE 3
PRE
P1
P2
P3
Edit
Updated: 05/22/2019
Pipeline Type
New Drugs in Development
Phase Of Development
Preclinical
Sponsors and Collaborators
Stoke Therapeutics
Mechanism of Action
Mechanism Description
Antisense Therapy - TANGO - Targeted Augmentation of Nuclear Gene Output - targeted to increase SCN1A RNA and increase Sodium Channel Nav1.1 expression
Populations Tested In
Dravet Mouse Model
Other Resources
Special FDA Designation
Nonprofit or Government Support
N/A
Nonprofit or Government Support Description
N/A
Previous Presentations
Presented at meetings (latest date) (Pipeline, AEDD; AES, Eilat, etc)
AEDD XV May 2019
Location of Clinical Trials
N/A
Clinical Trial link